Curated News
By: NewsRamp Editorial Staff
September 23, 2026
Quantum BioPharma Targets Multiple Sclerosis with Lucid-MS
TLDR
- Quantum BioPharma's Lucid-MS targets demyelination directly, offering a first-mover advantage in the underserved progressive MS market.
- Lucid-MS inhibits peptidyl arginine deiminase 2 to prevent myelin damage, addressing the neurodegeneration that drives long-term disability.
- Quantum BioPharma's Lucid-MS aims to reverse neurodegeneration, potentially restoring function and hope for millions living with multiple sclerosis.
- Quantum BioPharma's Lucid-MS takes a novel approach by blocking an enzyme to stop myelin destruction in multiple sclerosis.
Impact - Why it Matters
This news matters because multiple sclerosis affects millions globally, with no cure and limited options for progressive forms. Quantum BioPharma’s Lucid-MS, which targets an enzyme to inhibit demyelination, represents a novel approach that could potentially slow or reverse neurodegeneration. If successful, it would address a significant unmet need in MS treatment, offering hope to patients who currently face a future of increasing disability. The development also highlights the growing recognition of MS as a global health priority, as prevalence continues to rise. Investors and patients alike should watch this candidate closely, as it could reshape the treatment landscape for MS.
Summary
Nearly three million people worldwide are living with multiple sclerosis, a chronic disease in which the immune system attacks myelin, the protective coating around nerve fibers in the brain and spinal cord. In the United States alone, close to one million people are affected, a figure more than double what was previously assumed, according to a landmark study. Treatments for progressive forms of MS remain especially elusive, and recent research notes that no currently approved therapy directly reverses the neurodegeneration that drives long-term disability. This is the challenging landscape that Quantum BioPharma (NASDAQ: QNTM) is aiming to address with its lead drug candidate, Lucid-MS.
Quantum BioPharma’s approach is distinct: Lucid-MS is designed to inhibit demyelination directly by targeting an enzyme called peptidyl arginine deiminase 2. Rather than solely modulating the immune system, this mechanism seeks to protect myelin from damage, potentially offering a new path for better multiple sclerosis treatments. The company’s focus on progressive forms of MS, where existing therapies are limited, highlights the urgent need for innovation in this space.
The global prevalence of MS rose from about 2.3 million people in 2013 to nearly 2.9 million in 2020, underscoring the growing burden of the disease. With no cure available, new treatment strategies are critical. Quantum BioPharma’s efforts, while still in development, represent a promising avenue for addressing the neurodegeneration that leads to long-term disability. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma Targets Multiple Sclerosis with Lucid-MS
